Home » Topics » BioWorld Science, Patents

BioWorld Science, Patents
RSS

New dopamine receptor ligands reported by Neurogen

Oct. 11, 1996

Suntory reports agents for CNS and cerebrovascular disorders

Oct. 11, 1996

Japanese researchers report new antimetastatic agents

Oct. 11, 1996

DuPont Merck describes bisnaphthalimide anticancer drugs

Oct. 11, 1996

Farnesyltransferase inhibitors discovered by RPR

Oct. 11, 1996

Chemokine polypeptide from Human Genome Sciences has multiple potential uses

Oct. 11, 1996

Endorecherche claims EM-800 for estrogen-dependent disorders

Oct. 11, 1996

Schering AG's tubulin polymerization inhibitors for cancer

Oct. 11, 1996

Daiichi claims new taxol derivatives

Oct. 11, 1996

Pierre Fabre discloses topoisomerase II inhibitors

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.